Agilent Technologies Inc. (NYSE: A) and Proteome Systems, a leading international proteomics company, today announced they have signed a marketing agreement to collaborate on an integrated solution for the analysis of glycoproteins, molecules that are important in the study of many diseases, including cancer, influenza and arthritis. Under the agreement, Proteome Systems will make its GlycomIQ software, a comprehensive platform for the mass spectrometric analysis of protein-associated glycans (polysaccharides), compatible with the Agilent XCT, XCT Plus and XCT Ultra ion trap mass spectrometers.
Proteome Systems developed GlycomIQ to address the emerging field of glycomics, which examines how glycosylation, or the addition of sugars to proteins, affects biological processes and systems. GlycomIQ comprises kits, consumables and informatics software developed specifically for automated glycan analysis.
"Analysis of protein glycosylation is a demanding task that has often been reserved for specialized laboratories," said Nicolle Packer, executive vice president and head of glycoproteomics of Proteome Systems. "The combination of Agilent's robust, sensitive MS technology with our cutting-edge, automated glycomics system creates a powerful integrated solution that will streamline the study of glycoproteins."
The co-marketed product is expected to be available this summer. Agilent and Proteome Systems will also collaborate on the development of applications and seminars as part of the marketing agreement.
"Agilent is proud of this collaboration with Proteome Systems," said Taia Ergueta, general manager of Agilent's Proteomics and LC/MS business. "It illustrates our ongoing commitment to making leading-edge life science research accessible to more scientists and more laboratories. Using Agilent's protein separation and LC/MS products and Proteome Systems' GlycomIQ software, life scientists will be better able to produce, analyze and integrate complex data on the forefront of proteomics research."
Source : Agilent